Commercial Aspergillus fumigatus real-time PCR for invasive pulmonary aspergillosis: specialist evidence briefing

Why this paper matters

Invasive pulmonary aspergillosis remains difficult to diagnose early, particularly in patients with haematological malignancy, haematopoietic stem cell transplantation, intensive chemotherapy, corticosteroid exposure or profound immunosuppression. Culture is insensitive, histology is often unavailable, and radiology is not specific. Galactomannan has become a central biomarker, but performance varies by specimen type, antifungal exposure, host group and disease stage.

Aspergillus PCR has long been promising, but implementation has been limited by assay heterogeneity, extraction differences, target selection, contamination concerns, and variable interpretation across centres. A clinically evaluated commercial real-time PCR assay is therefore important because commercialisation may improve standardisation, reproducibility and adoption outside specialist mycology laboratories.

Clinical context

The diagnosis of IPA is usually probabilistic. Clinicians combine:

• host factors, such as neutropenia, haematological malignancy, transplantation or corticosteroid exposure;
• compatible imaging, especially nodules, halo sign, cavitation or infarct-like lesions on computed tomography;
• mycological evidence, including galactomannan, culture, microscopy, PCR or lateral-flow assays;
• clinical course and response to antifungal therapy.

In this setting, a commercial Aspergillus fumigatus real-time PCR assay could support earlier diagnosis, improve confidence in probable IPA classification, and potentially reduce unnecessary empirical antifungal treatment when used as part of a diagnostic algorithm.

Main finding

The paper evaluates a commercial Aspergillus fumigatus real-time PCR assay for the diagnosis of invasive pulmonary aspergillosis in patients with haematological malignancies. The clinical relevance lies in validating a defined assay in a high-risk population where early diagnosis directly affects antifungal timing and survival.

The specialist significance is not simply that PCR “works”. The key question is whether a commercial PCR assay offers sufficiently reliable analytical and clinical performance to be used alongside galactomannan and imaging in routine pathways.

What is genuinely new?

The novelty is likely to sit in one or more of the following areas:

• evaluation of a specific commercial assay rather than an in-house laboratory-developed test;
• clinical validation in a defined haematology population;
• comparison against established diagnostic categories such as proven/probable IPA;
• assessment of analytical performance, including limit of detection, reproducibility or specificity;
• potential contribution to standardisation of Aspergillus PCR implementation.

This is not a new concept in principle: Aspergillus PCR has been studied for many years. What is more clinically useful is the transition from heterogeneous in-house assays towards assays that can be validated, quality-assured and compared across centres.

Relationship to existing evidence

Recent reviews of molecular fungal diagnostics emphasise that PCR can improve the diagnosis of invasive fungal disease but remains limited by standardisation, assay availability and interpretation. A 2025 review in Diagnostics noted that PCR is sensitive and specific for invasive fungal disease, but that implementation remains constrained by limited standardisation, few commercial options, and lack of clear guidance for interpreting results.

That surrounding evidence makes this type of paper important. Commercial PCR assays do not automatically solve diagnostic uncertainty, but they can reduce one major barrier: between-laboratory variability.

Strengths to look for in the paper

• Clearly defined patient population, especially haematological malignancy or transplant subgroups.
• Use of accepted case definitions for proven, probable and possible IPA.
• Separate analytical and clinical performance assessment.
• Comparison with galactomannan, culture and radiology.
• Evaluation by specimen type, especially bronchoalveolar lavage fluid versus blood.
• Consideration of antifungal exposure before sampling.
• Reporting of sensitivity, specificity, positive predictive value and negative predictive value.

Limitations and cautions

PCR performance depends strongly on specimen type. Bronchoalveolar lavage fluid generally provides a higher organism burden than blood in IPA, but it is more invasive and may not be feasible in unstable or thrombocytopenic patients. Blood PCR is less invasive but may be less sensitive, especially in localised airway-invasive disease.

False positives may arise from colonisation, contamination or detection of non-invasive airway presence. False negatives may occur with low fungal burden, prior antifungal therapy, sampling timing, extraction inefficiency or inhibitors. A positive PCR result should therefore not be interpreted in isolation.

A further issue is species coverage. A narrowly targeted Aspergillus fumigatus assay may perform well for A. fumigatus but could miss non-fumigatus Aspergillus species or cryptic species with different susceptibility patterns. In haematology patients, that may matter for epidemiology and antifungal resistance surveillance.

Clinical implications

For specialist services, the likely implication is that commercial Aspergillus PCR should be considered as part of a multi-modal diagnostic pathway rather than as a standalone rule-in or rule-out test.

A practical diagnostic model might include:

• early CT imaging in high-risk patients with persistent fever or respiratory symptoms;
• serum galactomannan in appropriate host groups;
• bronchoalveolar lavage where clinically safe;
• BAL galactomannan, fungal culture, microscopy and Aspergillus PCR;
• azole resistance testing or sequencing where Aspergillus is detected;
• multidisciplinary interpretation with haematology, infectious diseases, respiratory and mycology input.

Implications for antifungal stewardship

A validated commercial PCR assay may support earlier targeted antifungal therapy, but also more confident de-escalation when combined with negative biomarkers and low radiological probability. The stewardship value depends on pathway design. PCR added without interpretive governance may increase diagnostic noise; PCR embedded into a structured algorithm may reduce unnecessary empirical therapy and improve diagnostic confidence.

Implications for UK specialist mycology services

For UK centres, this type of paper supports the case for:

• standardised fungal PCR pathways;
• clear reporting language for positive and negative results;
• integration with antifungal stewardship rounds;
• external quality assessment participation;
• reflex testing for resistance where feasible;
• collaboration between local laboratories and specialist mycology reference services.

Evidence strength

Conclusion

Commercial Aspergillus real-time PCR assays represent an important step towards standardised molecular diagnosis of invasive pulmonary aspergillosis. Their greatest value is likely to be in high-risk haematology pathways, especially when applied to bronchoalveolar lavage fluid and interpreted alongside galactomannan, culture, imaging and host risk.

The clinical message is not that PCR replaces existing tests. Rather, validated commercial PCR may strengthen diagnostic algorithms, improve early case recognition, support antifungal stewardship and reduce variation between laboratories.

References

1. Gibert C, Bigot J, et al. Clinical and analytical evaluation of a commercial Aspergillus fumigatus real-time PCR assay for the diagnosis of invasive pulmonary aspergillosis in patients with hematological malignancies.
   Journal details to confirm from PubMed record.
   PubMed
2. Brown L, Cruciani M, Morton O, et al. The molecular diagnosis of invasive fungal diseases with a focus on PCR.
   Diagnostics. 2025;15(15):1909.
   doi:10.3390/diagnostics15151909.
   PubMed
3. Patterson TF, Thompson GR, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America.
   Clinical Infectious Diseases. 2016;63(4):e1-e60.
   doi:10.1093/cid/ciw326.
   PubMed